Scientific deep-dive
A Biologic Plus Tirzepatide for Psoriasis
Everyone got the psoriasis biologic; half also got tirzepatide. The combination cleared skin better by 62 percentage points and reached 10% weight loss in 69.2% versus 9.1%.
Psoriasis and obesity travel together, and each makes the other harder to treat. A phase 3b trial did the obvious experiment for the first time: give everyone an effective psoriasis biologic, then add tirzepatide to half of them. The combination improved both the skin and the weight, by margins that are not close.[1]
What was added, and to what
This matters for reading the result. Both arms received ixekizumab, an established interleukin-17 inhibitor for moderate-to-severe psoriasis. The question was not whether a biologic beats a GLP-1 — it was what tirzepatide adds on top of treatment that already works.
On the skin endpoint the risk difference was 62.0 percentage points (95% CI 51.7 to 72.2). On weight, 69.2% of the combination group reached a 10% or greater reduction against 9.1% on the biologic alone — a difference of 60.0 points.[1]
Why obesity and psoriasis interact
Two plausible mechanisms sit behind this, and the trial does not separate them. Adipose tissue is metabolically active and inflammatory, so reducing it may reduce the inflammatory load driving the disease. Separately, biologic dosing is fixed rather than weight-based, so a heavier person receives less drug per kilogram — a well-recognized reason biologics underperform in obesity.
If the second mechanism dominates, the finding is partly about dose, not about GLP-1 biology. Either way the clinical answer is the same, but the two stories imply different things about which patients benefit most.
The cost side
Adverse events were generally consistent with the known profiles of both drugs, the commonest being gastrointestinal events and injection site reactions — and gastrointestinal events occurred more frequently with the combination.[1] Adding a drug adds its side effects; it does not blend them away.
There is also the obvious practical cost. Two injectable specialty medicines is an expensive combination and an access fight in most systems, and this trial says nothing about who will be able to obtain it. Our piece on how treatment gets allocated covers the mechanics of that.
It fits a broader pattern this class keeps producing: outcomes improving in people with an inflammatory disease. We looked at a large psoriasis cohort in when a hazard ratio is too good — where the mortality figure was not believable but the cardiac one was. This trial is the randomized version, and it is stronger evidence than any cohort.
Frequently Asked Questions
References
- 1.Lebwohl M, Blauvelt A, Kartman CE, et al. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial JAMA Dermatology. 2026. PMID: 42139049.
Related research
A Drug to Protect Muscle
A myostatin-targeting antibody tested alongside tirzepatide was well tolerated and, the authors conclude, effective at preserving lean mass. The published summary does not give the size of the effect.
5 min read
Beyond BMI: Who Actually Needs Treatment
Among people all above BMI 27, ten-year cardiovascular mortality ranged from 5.7% to 0.1%. And in trial participants, weight loss was similar across risk groups — so treating by risk costs nothing in effectiveness.
6 min read
Beyond the Scale: Blood Pressure, Lipids and What Else Changes
Pooling the individual records of 3,136 people, systolic blood pressure fell 4.95 mmHg further than placebo — and by about the same amount whether or not the person had hypertension.
7 min read
Can You Lower the Dose and Keep the Weight Off?
Stepping down to 5 mg held 16.6% of body weight lost against 21.9% for staying at the full dose. But rescue therapy went from 8% to 25% — and to 67% on placebo.
6 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% were consuming below estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
GLP-1 Drugs After 65: Strength, Not Just Weight
Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite — and no guidelines exist for this age group.
7 min read
Where to get tirzepatide (Mounjaro / Zepbound) online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
ShedRx
Oral orforglipron alongside the injectables
From $299/mo
Get started →Synergy Rx
Knowing which pharmacy fills the vial — it names Belmar Pharmacy
From $349/mo
Get started →MyDrHank
An oral route if you will not self-inject
From $349/mo
Get started →